Navigation Links
Genmab A/S - Changes Board/Management/Auditors

Genmab Announces Appointment of David Eatwell as New Chief Financial

Officer Summary: Genmab Announces the Appointment of David A. Eatwell as Chief

Financial Officer.

COPENHAGEN, Denmark, June 2 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) today announced that David A. Eatwell has been appointed Chief Financial Officer of the company. Mr. Eatwell will be responsible for overseeing the financial and accounting activities of the company.

David A. Eatwell, 47, joins Genmab with extensive experience and a proven track record in leading international life science businesses, having spent 15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwell served as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD 1.8 billion leading provider of manufacturing and packaging services for the pharmaceutical and biotech industry, with 33 facilities in 12 countries and 10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO of Cardinal Health, Inc., a fortune 20 global manufacturer and distributor of healthcare products and services, where he spearheaded the USD 3.3 billion sale of the Pharmaceutical Technologies and Services division to The Blackstone Group and was instrumental in creating the framework and building the infrastructure to support the newly created company, Catalent Pharma Solutions, Inc. Mr. Eatwell is a Chartered Accountant.

Mr. Eatwell is replacing Bo Kruse who has decided to seek new challenges elsewhere, but will during a transitional period be available for the company.

"We are very excited to have David Eatwell on board to be part of our Senior Management team and we are looking forward to working with him. We also wish to thank Bo Kruse for his many years of dedicated service to Genmab, and important contributions to the company. We wish Bo Kruse the best of luck in his future endeavors and would like to thank him for his efforts at Genmab since 2000", said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About Genmab A/S Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45-33-44-77 30, M: +45-25-27-47-13, E:

Stock Exchange Release no. 27/2008

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
(Date:10/12/2015)...  Rebiotix Inc. today announced that U.S. Food ... Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough ... difficile (C diff) infection, a challenging to ... in the U.S. annually. 1 Rebiotix is ... to revolutionize the treatment of debilitating GI diseases ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, Chairman ... firm as a Premier Expert consultant. NDA Partners Premier Experts are top ... to the company's clients. Premier Experts collaborate to design and implement critical ...
(Date:10/10/2015)... 10 octobre 2015 Le 8 octobre, l,honorable Doris ... Registre du Congrès sa déclaration de soutien à ... autour du plasma (IPAW), qui se tiendra du ... Plasma Protein Therapeutics Association (PPTA) et ... , Sensibiliser l,opinion publique mondiale autour du ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to ... introduce its product to market. The official announcement was recently ... Economy event in San Francisco , ... platform powered by IBM Watson. "It is both ... first 100 companies to bring to market the cognitive power ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):